Eastgate Biotech Corp(ETBI)
USD --+0.00%
Reward38Moderate
Risk40Moderate
📊75%Data
ETBI
+0.0 · +0.00%
USD · OTCCE
Eastgate Biotech Corp | Healthcare
Capital Destroyer
Market Cap:1.06M
ℹ️
Reward Rating
38
Moderate
Bottom 5% (model universe)
75% data coverage
ℹ️
Risk Rating
40
Moderate
Risk Assessment
75% data coverage
ℹ️

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

ℹ️ Educational tool only · More
Limited data coverage
We don't have enough public data on ETBI to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available for limited-coverage stocks
The overview tab requires fundamentals and price history we don't have for this stock. The price chart is the most reliable view we have — try the Chart tab.

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Eastgate Biotech Corp?

, a development stage company, develops novel formulations of natural compounds and pharmaceutical products.

ETBI · Verdict

Limited reward · moderate risk

ETBI stands out on volatility and balance sheet, but watch the profitability signal.

Based on 75% data coverage

ETBI · Verdict

What’s working & what to watch

Strengths 2

  • Volatility75/100

    Above average

  • Balance sheet68/100

    Current ratio 0.00

Watchouts 2

  • Profitability10/100

    0% return on equity

  • Growth41/100

    Earnings +20.1% CAGR

Model-based scoring. For information only — not financial advice.

What is Eastgate Biotech Corp?

, a development stage company, develops novel formulations of natural compounds and pharmaceutical products. The company is developing pharmaceutical products, such as Lorazepam oral spray for acute seizures emergency treatment; Ketoconazole 2% topical ointment for treatment of skin fungal infections; and Metformin chewable/ sublingual tablets for treatment of type 2 diabetes. The company is listed on the OTCCE in USA, operating in the Healthcare sector, with a market capitalisation of 1.06M.

Financial Highlights

Investment Breakdown

📈 Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
💰 Profitability
Thin or inconsistent margins weigh on earnings quality.
⚠️ Risk
Risk profile appears balanced versus broad market conditions.
💸 Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (38)

The scoring profile indicates weak reward characteristics across most factors, including valuation and momentum. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
Market Cap1.06M
P/E RatioN/A
Dividend YieldN/A
52 Week High0.0045
52 Week Low0.0001
Last AnnualDecember
IPO DateN/A
IncorporatedUSA
Shares Outstanding1B
No. of Employees2
IndustryBiotechnology
ExchangeOTCCE
Beta-4065.849
CurrencyUSD